About: Targeting Glycoproteins as a therapeutic strategy for diabetes mellitus and its complications

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Targeting Glycoproteins as a therapeutic strategy for diabetes mellitus and its complications Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Targeting Glycoproteins as a therapeutic strategy for diabetes mellitus and its complications
Creator	Seyed, & Farzaei, Mohammad Mohammad, & Tijjani, Habibu Chandra, Harish Farzaei, Hosein Mishra, Abhay Morais-Urano, Raquel Naseri, Rozita Navabi, Jafar Nigam, Manisha Olatunde, Ahmed Samimi, Zeinab
Source	Medline; PMC
abstract	OBJECTIVES: Glycoproteins are organic compounds formed from proteins and carbohydrates, which are found in many parts of the living systems including the cell membranes. Furthermore, impaired metabolism of glycoprotein components plays the main role in the pathogenesis of diabetes mellitus. The aim of this study is to investigate the influence of glycoprotein levels in the treatment of diabetes mellitus. METHODS: All relevant papers in the English language were compiled by searching electronic databases, including Scopus, PubMed and Cochrane library. The keywords of glycoprotein, diabetes mellitus, glycan, glycosylation, and inhibitor were searched until January 2019. RESULTS: Glycoproteins are pivotal elements in the regulation of cell proliferation, growth, maturation and signaling pathways. Moreover, they are involved in drug binding, drug transportation, efflux of chemicals and stability of therapeutic proteins. These functions, structure, composition, linkages, biosynthesis, significance and biological effects are discussed as related to their use as a therapeutic strategy for the treatment of diabetes mellitus and its complications. CONCLUSIONS: The findings revealed several chemical and natural compounds have significant beneficial effects on glycoprotein metabolism. The comprehension of glycoprotein structure and functions are very essential and inevitable to enhance the knowledge of glycoengineering for glycoprotein-based therapeutics as may be required for the treatment of diabetes mellitus and its associated complications. [Figure: see text]
has issue date	2020-01-31(xsd:dateTime)
bibo:doi	10.1007/s40199-020-00327-y
bibo:pmid	32006343
has license	no-cc
sha1sum (hex)	c63d396fba04b98754ccb6948cc4b00beb0f4bae
schema:url	https://doi.org/10.1007/s40199-020-00327-y
resource representing a document's title	Targeting Glycoproteins as a therapeutic strategy for diabetes mellitus and its complications
has PubMed Central identifier	PMC7095136
has PubMed identifier	32006343
schema:publication	Daru
resource representing a document's body	covid:c63d396fba04b98754ccb6948cc4b00beb0f4bae#body_text
is schema:about of	named entity 'comprehension' named entity 'effects' named entity 'metabolism' named entity 'glycoprotein' named entity 'regulation' named entity 'inevitable' named entity 'proteins' named entity 'Endoplasmic reticulum' covid:arg/c63d396fba04b98754ccb6948cc4b00beb0f4bae named entity 'biological effects' named entity 'stability' named entity 'diabetes mellitus' named entity 'therapeutic' named entity 'therapeutics' named entity 'diabetes mellitus' named entity 'strategy' named entity 'functions' named entity 'The' named entity 'composition' named entity 'proteins' named entity 'English language' named entity 'glycoprotein' named entity 'N-acetyl-D-glucosamine' named entity 'Targeting' named entity 'cell membranes' named entity 'carbohydrates' named entity 'glycoprotein' named entity 'glycoengineering' named entity 'diabetes mellitus' named entity 'efflux' named entity 'metabolism' named entity 'Glycoproteins' named entity 'glycoprotein' named entity 'diabetes mellitus' named entity 'Scopus' named entity 'glycoprotein' named entity 'Endoplasmic reticulum' named entity 'GlcNAc' named entity 'CD9' named entity 'nuclear magnetic resonance' named entity 'Glycoproteins' named entity 'T1D' named entity 'MODY' named entity 'serum half-life' named entity 'oligosaccharides' named entity 'oligosaccharides' named entity 'simple sugar' named entity 'O-glycosylation' named entity 'T2DM' named entity 'glycoprotein' named entity 'pancreas' named entity 'diabetes' named entity 'pancreatic hormone' named entity 'glycosylated' named entity 'amino acids' named entity 'glycoprotein' named entity 'cell membranes' named entity 'Breastfeeding' named entity 'diabetes' named entity 'Wistar' named entity 'glycoproteins' named entity 'allyl' named entity 'tryptophan' named entity 'adaptive immune' named entity 'proinflammatory cytokines' named entity 'hyperglycemia' named entity 'proline' named entity 'protein' named entity 'O-glycosylation'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software